Printer Friendly

HMRlignan provides cardiovascular protection.

Linnea has unveiled the results of a new study showing that 7-hydroxymatairesinol (HMRIignan, HMR) ingestion may provide cardiovascular protection by depressing a particular inflammatory pathway. The study, concluded in February, was performed by the Department of Clinical Medicine at the University of Insubria in Italy and is under preparation for publication.

Researchers evaluated the anti-inflammatory properties of HMRIignan, (from Norway Spruce, Picea abies) and its metabolite enterolactone on the production of tumor necrosis factor (TNF)-alpha in a human cell line (THP-I). The effect of HMRIignan was additionally assessed on the production of reactive oxygen species (e.g. free radicals) by polymorphonuclear leukocytes (PMNs). Researchers found that both HMR and enterolactone concentration-dependently reduced TNF-alpha production in THP-I cells, a known inflammatory pathway. In polymorphonuclear leukocytes, HMR concentration-dependently significantly reduced production of reactive oxygen species.

Commenting on the results, research pharmacologist, Dr. Marco Cosentino, stated, "These results indicate that HMR and enterolactone exert effects that may result in reduction of the inflammatory process, known to be a contributing factor in the etiology of heart disease. Tumor necrosis factor production by monocytes infiltrating atherosclerotic lesions is a key factor in the genesis and progression of vascular damage, and oxidative stress of the vascular wall sustained by circulating activated PMNs is an early step in the cascade leading to cardiovascular pathology in otherwise asymptomatic individuals. This study shows remarkable potential for the inclusion of HMR in a cardiovascular protective regimen."

For further information: 888-253-0044.

COPYRIGHT 2007 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH HIGHLIGHTS
Publication:Nutraceuticals World
Date:May 1, 2007
Words:241
Previous Article:Cyracos shown to be an anti-stress solution.
Next Article:Phase 2 decreases body fat, maintains lean body mass.
Topics:


Related Articles
Study Investigates Association of Air Pollution and Health Effects.
Hormos licenses HMRlignan to Linnea.
Linnea launches first branded ingredient.
Linnea: leveraging lignans.
Plant lignans inhibit growth of prostate cancer cells.
New study identifies 7-hydroxymatairesinol as key lignan in food sources.
HMRlignan reduces hot flashes.
REGENEREX REPORTS 2007 4TH QTR NET LOSS OF $3.5 MILLION.
The life lines of women: more products are appearing on the market to help women live longer and healthier.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters